| NCT ID | NCT05522374 |
| Status | Recruiting |
| Phase | — |
| Sponsor | LMU Klinikum |
| Condition | Neurodegeneration With Brain Iron Accumulation (NBIA) |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2012-06-14 |
| Primary Completion | 2040-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2012-06-14 with a primary completion date of 2040-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
TIRCON-reg aims to * continue the provision of a global registry and natural history study for NBIA disorders * harmonize and cover existing national and single site registries * enable participation of countries and single sites that so far have no access to an NBIA registry * join forces in order to recruit sufficient numbers of patients * define the natural history of NBIA disorders * define the most appropriate outcome measures * inform the design and facilitate the conduction of clinical trials
Eligibility Criteria
Inclusion Criteria: * suspected or confirmed NBIA * willingness to participate Exclusion Criteria: * unwillingness to participate
Contact & Investigator
Thomas Klopstock, Prof. Dr.
PRINCIPAL INVESTIGATOR
LMU Klinikum, Friedrich-Baur-Institute
Frequently Asked Questions
Who can join the NCT05522374 clinical trial?
This trial is open to participants of all sexes, studying Neurodegeneration With Brain Iron Accumulation (NBIA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05522374 currently recruiting?
Yes, NCT05522374 is actively recruiting participants. Contact the research team at boriana.buechner@med.uni-muenchen.de for enrollment information.
Where is the NCT05522374 trial being conducted?
This trial is being conducted at Ottawa, Canada, Prague, Czechia, Munich, Germany, Milan, Italy and 5 additional locations.
Who is sponsoring the NCT05522374 clinical trial?
NCT05522374 is sponsored by LMU Klinikum. The principal investigator is Thomas Klopstock, Prof. Dr. at LMU Klinikum, Friedrich-Baur-Institute. The trial plans to enroll 2,000 participants.